Semaglutide Tablets7mg

Key Selling Points of Semaglutide Tablets for Type 2 Diabetes

1. Superior Efficacy

• Powerful Blood Sugar Control: As a GLP-1 receptor agonist, it mimics natural GLP-1 to stimulate insulin secretion, inhibit glucagon release, and delay gastric emptying, effectively lowering blood sugar and improving HbA1c levels .

• Metabolic Benefits: Helps reduce weight and improve lipid profiles, lowering cardiovascular risk .

2. Convenient Administration

• Oral Formulation: No need for injections—simply take a daily pill, improving adherence for patients who prefer non-invasive treatment .

3. Strong Safety Profile

• Well-Tolerated: Most patients experience only mild gastrointestinal effects (e.g., nausea) that often subside over time .

• Low Hypoglycemia Risk: Minimal risk when used alone; can be safely combined with other medications with proper dose adjustments .

4. Flexible Dosing

• Gradual Titration: Start with a low dose (3mg) and increase step-by-step (up to 14mg) based on individual response, allowing the body to adapt .

5. Trusted Brand

• Developed by Industry Leaders: Co-created by Novo Nordisk (a global leader in diabetes care) and MSD, ensuring high-quality, reliable treatment .

Note: Must be used under medical supervision. Report any unusual symptoms promptly.

Function and Indications

Semaglutide tablets are a GLP-1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. By mimicking the action of natural GLP-1, it promotes insulin secretion, inhibits glucagon release, and delays gastric emptying, thereby lowering blood sugar levels.

Applicable Population

• Primary Use: Adults with type 2 diabetes who have inadequate glycemic control through lifestyle modifications alone.

• Combination Therapy: Can be used alone or in combination with other antidiabetic medications (e.g., metformin, sulfonylureas).

• Contraindications:

  ◦ Type 1 diabetes or diabetic ketoacidosis.

  ◦ Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

  ◦ Hypersensitivity to semaglutide or any excipients.

Usage and Dosage

• Starting Dose: 3 mg once daily, taken orally for at least 30 days.

• Dose Titration: After 30 days, increase to 7 mg once daily; if further glycemic control is needed, may increase to 14 mg once daily after another 30 days.

• Administration: Swallow the tablet whole with water, with or without food. Do not chew, crush, or split the tablet.

Adverse Reactions

• Common (≥5%): Nausea, vomiting, diarrhea, abdominal pain, constipation, headache, fatigue.

• Serious Risks:

  ◦ Thyroid C-cell tumors: Observed in animal studies; contraindicated in patients with MTC history/family history.